UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 21, 2016
ANAVEX
LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
| Nevada | 000-51652 | 98-0608404 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
51 West 52nd Street, 7th Floor, New
York, NY USA 10019
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 1-844-689-3939
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 7.01 Regulation FD Disclosure.
On October 21, 2016, an interview with the Chief Executive Officer of Anavex Life Sciences Corp., Christopher U. Missling was made available online by The Wall Street Transcript.
A transcript of the interview is being furnished herein and is also available at https://www.twst.com/
The information in this Current Report on Form 8-K, including the exhibit herein, is being furnished pursuant to this Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
| (a) | Not applicable. | |
| (b) | Not applicable. | |
| (c) | Not applicable. | |
| (d) | Exhibits. |
| EXHIBIT NO. | DESCRIPTION | LOCATION | ||
| Exhibit 99.1 | Transcript of Interview with Christopher Missling | Provided herewith |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | ||
| /s/ Christopher Missling | ||
| Name: Christopher Missling, PhD | ||
| Title: Chief Executive Officer | ||
| Date: October 21, 2016 |